Highline Wealth Partners’s Blueprint Medicines BPMC Stock Holding History

Highline Wealth Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42	Closed	-$5.38K	–	1089
2025 Q2	$5.38K	Hold	42	–	–	﹤0.01%	430
2025 Q1	$3.72K	Buy	+42	New	+$4.1K	﹤0.01%	498

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Highline Wealth Partners's BPMC Position: Q3 2025 in Review

Highline Wealth Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 42 shares — an estimated $5.38K sold.

Highline Wealth Partners first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $5.38K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Highline Wealth Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Highline Wealth Partners sold 42 Blueprint Medicines shares in Q3 2025, an estimated $5.38K.
Highline Wealth Partners first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
Highline Wealth Partners's Blueprint Medicines position peaked at $5.38K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Highline Wealth Partners's 13F filing for Q3 2025, filed 14 Oct 2025.